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Diagnosis
The most useful investigations are echocardiography and respiratory function tests. The echocardiogram may show a hypertrophied, dilated or hypokinetic right ventricle, tricuspid regurgitation and elevated pulmonary arterial pressure. The left ventricle usually contracts normally, but may be encroached upon by the enlarged right ventricle. In the absence of a tricuspid regurgitation jet, pulmonary arterial pressure cannot be determined on echocardiography and the diagnosis is not excluded using this test. Respiratory function tests show a disproportionate reduction in carbon monoxide diffusion in the lung (DLCO) (around 50% of predicted in moderate PAH), with at most a mild-tomoderate restrictive lung defect. The reduction in DLCO is greater than that seen with comparably symptomatic left heart failure.
The definitive test for PAH is right heart catheterisation, providing a direct measure of pulmonary pressures. Several Australian centres perform this as an outpatient procedure, via the right internal jugular vein under local anaesthetic. Anticoagulation does not need to be ceased and fasting is not required. Repetitive straight leg raising to increase cardiac demand may uncover early cases in which PAH is only present during exercise. The six-minute walk test is informative and safe in assessing response to treatment and has a strong independent association with mortality. 5 Once PAH has been detected, a comprehensive search for causes should be undertaken (Box 2).
Screening
Patients with family history of primary PAH may have a genetic predisposition to PAH, although the predictive value of the BMPR2 gene, which has been associated with the ■ New agents for PAH, now becoming available, improve symptoms and reduce pulmonary resistance, with some demonstrating an ability to reverse remodelling of the right ventricle.
■ Best management of PAH is comprehensive and multidisciplinary. Centres of excellence are needed in geographically strategic areas.
■ Aggressive efforts must be made to diagnose PAH and to disease, is not yet well defined. 6 Up to 15% of patients with scleroderma (especially limited scleroderma) ultimately develop PAH, and annual screening with DLCO measurement and echocardiography is advisable.
Treatment
PAH can be treated specifically (pulmonary thromboendarterectomy) or generically. Chronic thromboembolic pulmonary hypertension is increasingly recognised as an important cause of secondary PAH, for which pulmonary thromboendarterectomy may provide definitive treatment. 7 PAH secondary to sleep apnoea may respond to continuous positive airway pressure. 8 PAH complicating connective tissue disease is recognised as an independent predictor of poorer prognosis in these conditions. 9 Treatment here should be along similar lines to that used in primary pulmonary hypertension.
Until recently, access to effective drug treatment for severe PAH has been very limited in Australia. Heart-lung transplantation for primary pulmonary hypertension was first performed at St Vincent's Hospital, Sydney, in 1986. This was the first putative "curative" therapy for this condition, but is now appropriate only for patients with advanced disease for whom medical therapy has failed. There is, however, an increasing selection of vasodilator and remodelling agents becoming available, providing promise of effective long term medical alternatives. [10] [11] [12] [13] [14] British guidelines for the diagnosis and treatment of PAH were recently published and treatment algorithms are under development internationally. 15 
Medical therapies
The pathophysiological basis of PAH is an increase in vasoconstrictor substances (thromboxane, endothelin) and a reduction in vasodilatory substances (nitric oxide, prostacyclin) with smooth muscle cell proliferation and in situ thrombosis, resulting in structural reduction in pulmonary arterial lumen size and, ultimately, plexigenic arteriopathy.
Medical therapies for PAH (Box 3) consist of agents which modify one or more of these pathogenetic mechanisms: ■ anticoagulation (to prevent in situ thrombosis or thromboembolism; eg, warfarin, prostacyclin analogues); ■ vasodilators (eg, prostacyclin analogues, which increase intracellular cyclic AMP, calcium antagonists, endothelin antagonists, bosentan, and phosphodiesterase 5 inhibitors, which increase cyclic GMP); and ■ long term antifibrotic and remodelling agents (prostacyclin analogues and bosentan).
Atrial septostomy
For patients refractory to vasodilator therapy, atrial septostomy may be considered. The aim of this intervention is to relieve right-sided congestion and augment systemic cardiac output. Experience with this procedure in Australia is extremely limited, but its value has been suggested in a number of small studies in other countries. 24 
Natural history
PAH is often a lethal condition or contributes to a poor outlook, with the prognosis directly related to the severity of the associated right ventricular dysfunction. 2 Once right ventricular failure ensues, the median survival for patients without treatment is short. PAH, arising secondary to other disorders, contributes to exercise intolerance and reduces survival. 
Referral
With the increasing availability of effective treatment for severe pulmonary hypertension, it is important that patients are referred to centres offering the range of diagnostic and therapeutic interventions. Assessing dose response, monitoring clinical outcomes, switching agents and applying combination therapy (including different modalities) requires considerable experience to ensure optimal outcomes. Complex decisions are required in delineating patients with chronic thromboembolic pulmonary hypertension suitable for pulmonary thromboendarterectomy and the timing of listing for lung transplantation. These issues have been recently addressed in the United Kingdom where the National Health Service has designated national centres for the assessment and management of severe pulmonary hypertension. 15 In addition, one centre only has been nominated to perform pulmonary thromboendarterectomy surgery, so as to ensure concentration of experience and expertise.
Conclusion
Historically, Australia has been unable to offer patients with PAH adequate treatment, largely because of the high cost of therapy. The performance of pulmonary thromboendarterectomy in Australia was recently shown to achieve success rates similar to international practice. Transplantation continues to be limited by donor availability. Now, with the availability of new and effective oral agents, we can abandon the therapeutic nihilism of past decades, and offer patients effective therapies. Some of these agents allow reverse remodelling of the right ventricle within very short periods. Reverse remodelling of the pulmonary artery and the potential to reverse the entire disease process are realistic targets.
This new era of effective agents gives clinicians a sound reason to diagnose PAH, to tease out all contributing elements and to detect cases early. Trials to date have been performed in moderately to severely affected patients, but are now in progress in less ill patients. As with most cardiovascular diseases, earlier detection and intervention is likely to be rewarded with better outcomes. 
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